hepatitis C
See the following -
A Law Professor’s Big Idea for Combating Greedy Drug Company Titans Like Martin Shkreli
In 2015, CEO of Turing Pharmaceuticals Martin Shkreli infamously raised the price of the life-saving drug Daraprim by 5,000%. Daraprim, developed more than 60 years ago, is used to treat the deadly parasitic infection toxoplasmosis. It was selling for $13.50 a pill; then Turing raised the price to $750. The move sparked massive backlash and Congressional hearings, and Shkreli himself was eventually arrested for, and convicted of, unrelated securities fraud charges. But the original, horrible problem didn’t get fixed. Turing kept the price sky-high; as of August 2016, many patients were paying $375 per pill...
- Login to post comments
Conshohocken-Based Non-Profit Aims to Revolutionize Biopharma
What if the next big thing in biopharma wasn’t produced by one of the big pharma companies that line the Northeast corridor between Philadelphia and New York City, but by a whole bunch of them? Conshohocken-based TransCelerate BioPharma is attempting to accomplish this difficult feat by embracing cooperation instead of competition. It is a 501(c)3 non-profit consortium of 18 pharmaceutical companies (and growing) that works with the FDA and global regulators to advance the industry through collaboration with researchers, industry organizations, and federal oversight agencies...
- Login to post comments
Cyber-Attacks on Healthcare Institutions on the Rise: Public Health Watch Report
With news this week that White House officials were fooled by a self-proclaimed “email prankster”—who posed as Jared Kushner, President Donald Trump’s advisor and son-in-law, and recently ousted Chief of Staff, Reince Priebus, during correspondences with various cabinet members—it’s worth remembering that there are cybersecurity implications for healthcare institutions as well...
- Login to post comments
Healthcare Big Data Silos Prevent Delivery of Coordinated Care
Complaints about silos in healthcare are nothing new. For a patient to fill a single prescription, there are several disconnected groups that need to work together to move the process forward. The specialist and the primary doctor have to connect and share information, and the payer and provider need to be on the same page. Unfortunately, for patients across the country, these stakeholders are moving at different speeds and in different directions, preventing true collaboration across organizations...
- Login to post comments
Hepatitis C Drug Costing VA, DoD Millions
One of the costliest drugs on the market threatens the Veterans Affairs Department's health budget — to the point that VA, which added the medication to its formulary in April, provides it to only the sickest patients who need it...
- Login to post comments
IBM And University Scientists Launch Global Computing Effort To Find Cures For Dengue, West Nile, And Hepatitis C Diseases
Researchers Say the 50,000 Years of Computer Time Needed to Discover Cures May Be Achieved in One Year Using World Community Grid Read More »
- Login to post comments
Let's Pay For Open Source With A Closed-Source Software Levy
This column has often explored ways in which some of the key ideas underlying free software and open source are being applied in other fields. But that equivalence can flow in both directions: developments in fields outside the digital world may well have useful lessons for computing...
- Login to post comments
Medicines for Malaria Venture Releases Report on how R&D Partnerships Serving Neglected Communities have Developed Dozens of Life-Saving Innovations Since 2010
The public-private initiatives that contributed to COVID-19 vaccine and drug development have showcased a model for accelerating biomedical innovation. This is another powerful example of how public-private partnerships have established themselves as powerhouses for fighting global health threats. According to a new report launched today from a group of 12 product development partnerships (PDPs), over the last decade, such alliances have brought to market 66 new drugs, vaccines, diagnostics and other technologies for a number of diseases—including tuberculosis, malaria, HIV, meningitis and sleeping sickness. These innovations have reached and benefitted more than 2.4 billion people in low-income countries.
- Login to post comments
Mylan Isn't Alone: 11 Drugmakers with Off-the-Charts Pricing Power
Mylan (MYL) is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. But it’s far from being the drug company with the most pricing power. Gilead (GILD), Biogen (BIIB) and Amgen (AMGN), along with eight other drug giants in the Standard & Poor's 500, enjoyed off-the-charts pricing power on their products relative to costs — far beyond Mylan's, according to a USA TODAY analysis of data from S&P Global Market Intelligence...
- Login to post comments
On the Lack of Good Medical Evidence for the New $100,000 Hepatitis C Drug Treatments
As we wrote, most recently last week, the hepatitis C screening and treatment bandwagon keeps rolling along. There is constant public argument whether about the prices of treatment regimens, which approach $100,000 per patient in the US...However, starting in March, 2014, we have posted about the lack of good evidence from clinical research suggesting these drugs are in fact so wondrous...
- Login to post comments
Startup Emocha's App To Help Baltimore Patients Manage Tuberculosis
Baltimore health IT startup Emocha Mobile Health Inc. is partnering with Baltimore City to test out its medication adherence application with tuberculosis patients...
- Login to post comments
Telehealth Progress Requires Beefed Up Network Infrastructure
Federal agencies have applied telehealth technology in innovative ways to expand health care beyond the walls of veterans' hospitals and other care facilities. Current efforts allow caregivers to reach patients in their daily lives while clinicians and specialists can share and archive medical information...
- Login to post comments
‘Superbug’ Scourge Spreads as U.S. Fails to Track Rising Human Toll
Fifteen years after the U.S. declared drug-resistant infections to be a grave threat, the crisis is only worsening, a Reuters investigation finds, as government agencies remain unwilling or unable to impose reporting requirements on a healthcare industry that often hides the problem...
- Login to post comments